Guilleminault C, Tharp BR, and Cousin D:  HVA and 5HIAA CSF measurements and 5HTP trials in some patients with involuntary movements . Neurol Sci 1973;;18:435-441.
Davidson DLW, Yates CM, Mawdsley C, et al:  CSF studies on the relationship between dopamine and 5-hydroxy-tryptamine in parkinsonism and other movement disorders . J Neurol Neurosurg Psychiatry 1977;;40:1136-1141.
Papeschi R, Molina-Negro P, Sourkes TL, et al:  The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF: Studies in patients with extrapyramidal disorders, epilepsy, and other diseases . Neurology 1972;;22:1151-1159.
Gottfries CG, Gottfries I, Johansson B, et al:  Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex . Neuropharmacology 1971;;10:665-672.
Bowers M, Gerbode FA:  Relationship of monoamine metabolites in human cerebrospinal fluid to age . Nature 1968;;219:1256-1257.
Faull KF, Kraemer HC, Barchas JD, et al: Â Clinical application of the probenecid test for measurement of monamine turnover in the CNSÂ . Biol Psychiatry 1981;;16:879-899.
Bowers MB:  Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: Reliability and interpretation of cerebrospinal fluid acid monoamine metabolite measures . Neuropharmacology 1972;;11:101-111.
Stahl SM, Berger PA:  Bromocriptine, physostigmine and neurotransmitter mechanisms in the dystonias . Neurology 1982;;32:889-892.
Faull KF, Anderson PJ, Barchas JD, et al:  A selected ion monitoring assay for biogenic amine metabolites and probenecid in human lumbar cerebrospinal fluid . J Chromatogr 1972;;163:337-349.
Berger PA, Faull KF, Kilkowski J, et al:  CSF monoamine metabolites in schizophrenia and depression . Am J Psychiatry 1980;;137:174-180.
Caraceni T, Calderini G, Consolazione A, et al:  Biochemical aspects of Huntington's chorea . J Neurol Neurosurg Psychiatry 1977;;40:581-587.
Chase TN:  Biochemical and pharmacologic studies of monamines in Huntington's chorea , in Barbeau A, Chase TN, Paulson GW (eds): Huntington's Chorea, 1872-1972: Advances in Neurology . New York, Raven Press, 1973;, vol 1, pp 533-542.
Curzon G, Gumpert J, Sharpe D:  Amine metabolites in the cerebrospinal fluid in Huntington's chorea . J Neurol Neurosurg Psychiatry 1973;;21:1337-1340.
Shista SK, Templer DI:  Cerebrospinal fluid amine metabolic end-products: Biochemical correlates of intelligence . Res Commun Chem Pathol Pharmacol 1975;;12:601-604.
Klawans HL:  Cerebrospinal fluid homovanillic acid in Huntington's chorea . J Neurol Sci 1971;;13:277-279.
Yates CM, Magill BE, Davidson D, et al:  Lysosomal enzymes, amino acids, and acid metabolites of amines in Huntington's chorea . Clin Chim Acta 1973;;44:139-145.
Mattsson B, Persson SA:  Cerebrospinal homovanillic acid and 5-hydroxyindole acetic acid in Huntington's chorea . Acta Psychiatry Scand 1974;;255(
(suppl)
):245-259.
Chase TN, Wexler NS, Barbeau A (eds): Huntington's Disease. Advances in Neurology . New York, Raven Press, 1979;, vol 23.
Bird ED:  Chemical pathology of Huntington's disease . Ann Rev Pharmacol Toxicol 1980;;20:533-551.
Spokes EGS:  Dopamine in Huntington's disease: A specific study of postmortem brain tissue , in Chase TN, Wexler NS, Barbeau A (eds): Huntington's Disease: Advances in Neurology . New York, Raven Press, 1979;, vol 23, pp 481-493.
Cowdry RW, Ebert MH, van Kammen DP, et al:  Cerebrospinal fluid probenecid studies: A reinterpretation . Biol Psychiatry 1983;;18:1287-1299.
Wode-Helgodt B, Sedvall G:  Correlations between height of subject and concentrations of monoamine metabolites in cerebrospinal fluid from psychotic men and women . Commun Psychopharmacol 1978;;2:177-183.
Siever L, Kraemer H, Sack R, et al:  Gradients of biogenic amine metabolites in cerebrospinal fluid . Dis Nerv Syst 1975;;36:13-16.
Eldridge R, Fahn S (eds): Dystonia: Advances in Neurology . New York, Raven Press, 1976;, vol 14.
Fann WE, Smith RC, Davis JM, et al (eds): Tardive Dyskinesia: Research and Treatment . New York, SP Medical & Scientific Books, 1980;.
Baldessarini RJ, Tarsy D:  The pathophysiologic basis of tardive dyskinesia , in Fann WE, Smith RC, Davis JM, et al (eds): Tardive Dyskinesia: Research and Treatment . New York, SP Medical & Scientific Books, 1980;, pp 181-186.
Pind K, Faurbye A:  Concentration of homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid after treatment with probenecid in patients with drug-induced tardive dyskinesia . Acta Psychiatr Scand 1970;;46:323-326.
Nagao T, Ohshimo T, Mitsunobu K, et al:  Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor . Biol Psychiatry 1979;;14:509-523.
Chase TN, Gordon EK, Ng LKY:  Norepinephrine metabolism in the central nervous system of man: Studies using 3-methoxy-4-hydroxy-phenylethylene glycol levels in cerebrospinal fluid . J Neurochem 1973;;21:581-587.
Curzan G:  Involuntary movements other than parkinsonism: Biochemical aspects . Proc R Soc Med 1973;;66:873-876.
Lal S, Allen J, Etienne P, et al:  Dopaminergic function in Gilles de la Tourette's syndrome, Sydenham's chorea and torsion dystonia . Clin Neurol Neurosurg 1976;;79:66-69.
Tabaddor K, Wolfson LI, Sharpless NS:  Diminished ventricular fluid dopamine metabolites in adult-onset dystonia . Neurology 1978;;28:1254-1258.
Wolfson LI, Sharpless NS, Thal LJ, et al:  Decreased ventricular fluid norepinephrine metabolite in childhood-onset dystonia . Neurology 1983;;33:369-372.